by Manon FRACHON | 2 Jun Mon | Without category
Pascal Touchon will reinforce Jeito’s expertise by bringing over 35 years of global experience in drug development, commercial activities, operational and strategic leadership at major international pharmaceutical groups and biotech companies. He will support...
by Manon FRACHON | 21 May Wed | Without category
Proceeds from the financing will advance ReproNovo’s lead candidates RPN-001 (leflutrozole) and RPN-002 (nolasiban), through Phase 2 clinical trials in male infertility and in the treatment of adenomyosis and embryo implantation, respectively. In the context of...
by Manon FRACHON | 24 Mar Mon | English
Proceeds from the financing will advance Augustine’s lead candidate, AGT-100216, through a Phase 2 proof-of-concept clinical trial in Charcot-Marie-Tooth and support significant pipeline expansion into cardio-metabolic and neurodegenerative diseases. This investment...
by Manon FRACHON | 3 Mar Mon | English
Callio Therapeutics is a biotechnology company developing multi-payload ADCs with technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience. Investment will contribute to achieve clinical proof-of-concept for Callio’s HER-2-targeted...
by Manon FRACHON | 7 Jan Tue | English
Proceeds of financing will support two double-blinded Phase 2 trials for its lead candidate XC001, a pioneering transformative gene therapy approach for the treatment of severe cardiovascular disease. This investment builds on Jeito’s expertise in cardiology,...
Recent Comments